Hamish Aitken-Buck: New Insights Challenge the Role of Histidine Rich Glycoprotein in Thrombosis
Hamish Aitken-Buck, Clinical Research Strategist at Thrombosis Research Institute, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Really pleased to see our latest study now available on medRxiv, the result of a great collaboration between the Thrombosis Research Institute, London and colleagues at Duke and McMaster.
Using data from more than 50,000 participants in the UK Biobank Pharma Proteomics Project, we applied a two-sample Mendelian randomisation approach to investigate whether genetically predicted levels of histidine-rich glycoprotein (HRG) are causally associated with thrombosis risk. Somewhat surprisingly, we found no evidence of an association with either arterial or venous thrombosis.
As often happens in research, the findings raise as many questions as they answer.
- How does the rs9898 variant affect HRG function?
- Why does its relationship with HRG protein levels differ across proteomic platforms?
- And if HRG influences coagulation and thrombogenesis in experimental models, why doesn’t this appear to translate into clinical thrombotic outcomes?
Plenty of new questions to explore.
Many thanks to all the collaborators who made this work possible.”
Title: Histidine-rich glycoprotein is not associated with thrombosis in a UK Biobank Mendelian randomisation analysis
Authors: Yuncheng Duan, Hamish M. Aitken-Buck, Peter MacCallum, Jeffrey I. Weitz, Ajay K. Kakkar, Andrew S. Allen
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 17, 2026, 20:38Konstantinos Bistas: Reduced Circulating Tregs in Pediatric Chronic Neutropenia
-
Sep 17, 2026, 15:33Gopal Patidar: Honoured to Contribute to the ASFA 2026 Guidelines for Therapeutic Apheresis
-
Sep 17, 2026, 20:36Cosima C. Hoch: Developing a 3D Organotypic Co-Culture Model for Pleomorphic Adenoma
-
Sep 17, 2026, 20:19Riten Kumar: Boston Children’s Hospital Ranked No. 1 in Seven Pediatric Specialties
-
Sep 17, 2026, 20:17Katrina Snow: Whole Blood or Component Therapy – Which Would You Choose?
-
Sep 17, 2026, 16:30Daria Camilli: Empowering Bleeding Disorder Advocacy Through Health Economics
-
Sep 17, 2026, 16:17Mehran Ghasemzadeh: Platelet NK Cell Crosstalk in Advanced Coronary Artery Disease
-
Sep 17, 2026, 16:16Barbara Adams Krolak: Do GLP-1s Affect Blood Clot Risk?
-
Sep 17, 2026, 15:46Heghine Khachatryan: Clinical Context at the Core of Thrombosis and Thrombophilia Management